Oocyte collection, culture and microinjection. Ovaries were isolated from 4-6 week-old female mice of the MF1 strain 46-48 h after intra-peritoneal injection of 7.5-10 international units (IU) of pregnant mare's serum gonadotrophin (PMSG; Intervet). Ovaries were placed in a Petri dish with pre-warmed (37°C) M2 medium (Sigma, Poole, UK) supplemented with 3-isobutyl-1-methylxanthine (IBMX; Sigma) so as to prevent oocytes from undergoing germinal vesicle breakdown (GVBD). Fully grown, GV-intact oocytes were released by puncturing antral follicles with a fine needle on the stage of a dissecting microscope. Oocytes were microinjected as described previously(S1). Injection volumes were estimated at 5% of the total ooplasmic volume (estimated to be 250 pl) by cytoplasmic displacement. Following microinjection and for in vitro maturation, oocytes with a clearly visible GV were transferred into micro-drops of M16 medium (Sigma) under mineral oil (Sigma) at 37°C in a humidified atmosphere of 5% CO 2 in air.
Morpholinos and cRNA constructs. For depletion of Mad2, Cdh1 and securin, we used morpholinos as described previously(S1-S6). For mock-depletion, we utilized a standard control morpholino (ControlMO) (S2, S3) . For depleting BubR1 in mouse oocytes, a morpholino designed to target murine BubR1 (NM_009773) designated BubR1MO (5′-TGG CTT CAC TCG CCT CCG CCA TCC T-3′) was microinjected at a pipette concentration of 2 mM. All morpholinos were supplied by Gene Tools (Gene Tools LLC, Philomath, OR, USA). Our previous results regarding Mad2 function in MI oocytes that were obtained using morpholinos (S2) have recently been recapitulated in oocytes from heterozygote Mad2 +/-mice(S7) thereby highlighting the physiological relevance of this in vitro approach and validating morpholinos as a robust experimental tool.
As part of the validation of BubR1MO's specificity, we utilised a cRNA encoding full-length human BubR1 (hBubR1)(see Fig. 1B and 2B) . This was necessary as we needed to use a sequence that would not be targeted by BubR1MO; hBubR1 cRNA would satisfy this requirement as it differs from murine BubR1 by 9 bases in the target sequence of BubR1MO. The ability of hBubR1 cRNA to rescue both the prophase I arrest defect (Fig. 1B) and the prometaphase I arrest (Fig. 2B ) induced after injection of BubR1MO confirms that these phenotypes are indeed the consequence of BubR1-depletion and are not due to an off-target effect of BubR1MO.
The mMESSAGE mMACHINE T7 Ultra kit (Ambion) was used to make cRNA's by T7-promoter driven in vitro transcription. TruClones containing ORFs encoding full-length mCdc20 (NM_023223) or mCdh1 (NM_019757) sequences located downstream of a T7-promoter within the pCMV6-Kan/Neo vector (OriGene) were linearised for use as cDNA templates for in vitro transcription. For hBubR1 cRNA, the full-length hBubR1 sequence subcloned into the pcDNA-3 vector(S8) (Invitrogen) containing a T7-promoter (a kind gift from Stephen Taylor, Faculty of Life Sciences, University of Manchester, UK) was linearised to serve as template for in vitro transcription. The cRNAs were polyadenylated, purified and dissolved in nuclease-free water and injected at a final concentration of approximately 0.5-1 µg/ml.
Western blotting. For sample collection, oocytes were washed in PBS/PVA, lysed in LDS sample buffer (NuPAGE; Invitrogen) and snap-frozen and stored at -80°C until used. For blotting, samples were thawed on ice before adding reducing agent (NuPAGE; Invitrogen) and boiled for 70°C for 10 minutes. Proteins were separated on 4-12% Bis-Tris gels (NuPAGE; Invitrogen) and transferred to PVDF membranes (Immobilon-P; Millipore) using the XL II Blot Module (Invitrogen). Following transfer, membranes were blocked for 1 h at room temperature in 3% BSA in PBS containing 0.05% Tween. Primary antibody incubation was undertaken overnight at 4°C in blocking solution. Primary and secondary antibodies for detecting Cdc20, Cdh1, securin, cyclin B1, actin and GAPDH were used as described previously (S2, S4, S5) . For detecting BubR1, a sheep polyclonal anti-hBubR1 antibody(S9) (a kind gift from Stephen Taylor, Faculty of Life Sciences, University of Manchester, UK) was used as the first layer followed by an HRP-conjugated anti-sheep antibody (Sigma) as the second layer. HRP-conjugated secondary antibodies were detected using ECL Plus (GE Healthcare) and protein bands were semi-quantitatively assayed using the ChemiDoc XRS Imaging System (Bio-Rad).
Immunocytochemistry. For immunolabelling, oocytes were fixed and stained as described previously (S2, S3, S10, S11) . For staining tubulin, a rat monoclonal antibody against ∝-tubulin (Abcam) was used as the first layer followed by an Alexa Fluor 633-conjugated goat anti-rat secondary (Invitrogen). For staining BubR1, the sheep polyclonal primary antibody described above for immunoblotting was used in combination with an Alexa Fluor 488-conjugated donkey anti-sheep secondary (Invitrogen). For staining Mad2, rabbit anti-Mad2 antiserum (a kind gift from Katja Wassmann, CNRS UMR7622, France)(S11) was used as the first layer followed by an Alexa Fluor 546-conjugated goat anti-rabbit secondary (Invitrogen). For labelling constitutive kinetochore components, human autoimmune serum (CREST) was used (a kind gift from William Earnshaw, Wellcome Trust Centre for Cell Biology, University of Edinburgh, UK) as the first layer followed by an Alexa Fluor 546-conjugated goat anti-human secondary (Invitrogen). DNA was stained by bathing oocytes in Hoechst 33342 (10 µg/ml; Sigma) for 5 min. Images were captured using a LSM 510 META confocal microscope (Carl Zeiss Microimaging) as described previously(S1, S 4). Images were processed using MetaMorph software and assembled into panels using Adobe Photoshop. (ΔhBubR1  KEN26AAA ) accelerates MI by ~2 h. To further interrogate a potential Cdc20-directed SAC role, we utilised a mutant form of hBubR1. In yeast and mammalian somatic cells, a conserved N-terminal APC-targeting KEN box motif in BubR1 (Mad3 in yeast) is essential for Cdc20 inhibition and thus for SAC function(S14, S15). We mutated this KEN box (KEN26) in hBubR1 to AAA (termed ΔhBubR1 KEN26AAA ). GV-stage oocytes were microinjected with ΔhBubR1 KEN26AAA cRNA and maintained for 2 h in 50 µM IBMX before being washed into IBMX-free medium to allow resumption of MI. Oocytes were then scored for the presence of polar bodies alongside control uninjected oocytes at hourly intervals starting from 6 h post-GVBD. Data were compiled from 3 separate experiments. The effect produced by ΔhBubR1
KEN26AAA was similar to the ~2 h acceleratory effect brought about by Mad2-depletion ( Fig. 2A) (S2) suggesting that ΔhBubR1
KEN26AAA exerted a dominant-negative effect on SAC function, reinforcing the contention that BubR1 can target Cdc20 during MI. Further in support of this notion, hBubR1-351-700 (which lacks both N-terminal KEN boxes) exerts a dominantinterfering effect in mitosis(S16) and also accelerates MI in mouse oocytes by ~2 h(S17). (A) Securin and cyclin B1 levels increase progressively until 6 h post-GVBD after which destruction commences and becomes evident by 8 h post-GVBD in controls. Samples (50 oocytes) were collected at the GV-stage and at 2 h, 4 h, 6 h and 8 h post-GVBD and immunoblotted for BubR1, cyclin B1, securin and actin. Note that BubR1 undergoes net synthesis during progression through MI as observed previously for Mad2 (S2) . (B) Securin and cyclin B1 are stable after BubR1-depletion. Samples (30 oocytes) of control oocytes and BubR1-depleted oocytes were collected at 8 h post-GVBD and immunoblotted for BubR1, cyclin B1, securin and GAPDH. Note that cyclin B1 is partially degraded and securin almost completely degraded by 8 h post-GVBD in controls (A and B) whereas in BubR1-depleted oocytes both proteins remain stable (B) (see also Fig. 2C ). (A to C) GV-stage oocytes were injected with hBubR1 cRNA and maintained overnight in 200 µM IBMX along with uninjected control oocytes before being washed into IBMX-free medium to allow resumption of MI. Samples (20 oocytes per timepoint) were collected at 3 h, 6 h and 8 h post-GVBD for controls and at 3 h and 6 h post-GVBD for hBubR1 cRNA-injected oocytes and blotted for BubR1, securin, Cdh1 and actin (A). Band intensities for Cdh1 (B) and securin (C) were quantified and normalised to controls. Shown is a representative blot (A) from 3 separate experiments. Data are presented as the mean + SEM. Asterisks denote significant differences (P < 0.05; Student's t-test) between mean levels of Cdh1 and securin in cRNA-injected oocytes and controls at the corresponding time-points post-GVBD. Note that in BubR1-over-expressing oocytes, Cdh1 is higher at 3 h and 6 h post-GVBD and that by 6 h post-GVBD securin is already reduced to levels found in controls at 8 h post-GVBD. (D) BubR1 over-expression accelerates transit through MI. GV-stage oocytes were injected with BubR1MO or hBubR1 cRNA, maintained for 24 h in 200 µM IBMX along with uninjected control oocytes before being washed into IBMX-free medium to allow resumption of MI. Oocytes from each group were scored for the presence of polar bodies at 6 h, 7 h, 8 h, 9 h and 10 h post-GVBD. Note that compared to controls, PBE occurs about 30 min earlier for oocytes over-expressing hBubR1 and that BubR1MO induces a marked inhibition of PBE. Figure S5 . Securin levels are higher after Cdh1-knockdown on a background in which securin synthesis is restrained. On the basis that securin gradually rises during the first 6 h post-GVBD ( fig. S3A ), our findings that suggest APCCdh1-mediated destruction of securin during prometaphase I (see Fig. 3 , D to F) suggested that ongoing low-level securin degradation during prometaphase I was being masked by more prominent securin synthesis. In order to explore this, we inhibited securin synthesis using a recently described securintargeting morpholino (termed SecMO)(S4). GV-stage oocytes were either injected with Cdh1MO or left uninjected and cultured for 24 h in 200 µM IBMX before being injected with SecMO. Oocytes were maintained for a further 1 h in IBMX before being washed into IBMX-free medium to allow resumption of MI. Following SecMO injection, we allowed oocytes to resume MI after only 1 h so as to prevent securin synthesis without producing the near-complete knockdown induced by extended (24 h) SecMO incubation(S4). Samples (30 oocytes per time-point) were collected along with uninjected oocytes at 3 h, 6 h and 8 h post-GVBD and immunoblotted for securin and actin. An additional sample at 9 h post-GVBD for uninjected oocytes shows near-complete degradation of securin at this stage (A). Securin band intensities on blots were quantified and normalised to values found in controls (B). Shown in (A) is a representative blot from two separate experiments. These data show that when securin synthesis was inhibited, Cdh1-depleted oocytes exhibited 2-3-fold more securin than Cdh1-replete controls, corroborating other data demonstrating APCCdh1-dependent securin destruction during early prometaphase I (see Fig. 3 , D to F). Thus, low-level APCCdh1-mediated securin destruction occurs in early prometaphase I (these data) ahead of precipitous APCCdc20-mediated destruction at anaphase I and MI exit (S2, S6, S10) . Figure S6 . Securin levels are reduced when Cdh1 is over-expressed. Given that securin is increased on a Cdh1-knockdown background, one prediction is that Cdh1 over-expression would reduce securin. Here we tested this using Cdh1 cRNA. GV-stage oocytes were either injected with BubR1MO or left uninjected and maintained for 24 h in 200 µM IBMX before being injected with Cdh1 cRNA and maintained for a further 2 h in 200 µM IBMX to allow time for Cdh1 translation. Oocytes were then washed into IBMX-free medium to allow resumption of MI and samples (30 oocytes per time-point) were collected along with uninjected oocytes at 3 h post-GVBD and immunoblotted for securin, cyclin B1, Cdh1 and GAPDH (A). Band intensities of securin, cyclin B1 and Cdh1 on blots were quantified and normalised (B). Shown is a representative blot from three separate experiments. Data are presented as the mean + SEM. Asterisks denote significant differences in mean securin and Cdh1 levels when compared with levels in controls (P < 0.0001; Student's t-test). These data show that over-expression of Cdh1 from exogenous Cdh1 cRNA in wild-type oocytes more than halved securin levels in early prometaphase I consistent with the notion that securin destruction intensified in the face of increased APCCdh1 activity. Added to this, injection of Cdh1 cRNA into BubR1-depleted oocytes, could restore Cdh1 to levels comparable to that in controls and this resulted in a corresponding reduction of securin. Note that in keeping with the lack of effect of Cdh1-depletion on cyclin B1 levels (see Fig. 3 , D and F), Cdh1-overexpression also did not affect cyclin B1. Figure S7 . Changes in the levels of securin and Cdh1 are proportional to the degree of BubR1-depletion. Previous data indicated that ~80% depletion of BubR1 (see fig. S1 ) resulted in increased levels of securin and reduced levels of Cdh1 (see Fig. 3 ). If these effects were specific to BubR1-depletion, one prediction is that the magnitude of effect on securin and Cdh1 levels should be proportional to the degree of BubR1-depletion. We therefore examined the effects of lesser degrees of BubR1-depletion on securin and Cdh1 levels. In order to induce varying severities of BubR1-knockdown, GV-stage oocytes were injected with BubR1MO and maintained in IBMX for varying lengths of time (24 h, 4 h and 0 h) before being washed out of IBMX. Immunoblotting confirmed that this strategy did indeed produce varying degrees of BubR1-knockdown (B). (A) PBE rates were determined for the three BubR1MO-injected groups along with uninjected controls at 10 h and 20 h post-GVBD. Error bars, mean ± SEM. (B) Samples (30 oocytes per time-point) of BubR1MO-injected oocytes incubated for 4 h [+BubR1MO (4h)] and for 24 h [+BubR1MO (24h)] were collected along with uninjected oocytes at 3 h post-GVBD and immunoblotted for BubR1, securin, cyclin B1, Cdh1 and Actin. Note that increasing severity of BubR1-depletion induces an increasing severity of MI arrest (A) along with increasingly marked changes in securin and Cdh1 but no effect on cyclin B1. Figure S8 . Rescue of MI arrest in BubR1-depleted oocytes by rectifying an APCCdc20/securin imbalance. We sought to redress the presumed APCCdc20/securin mismatch by microinjecting either Cdc20 cRNA (to increase Cdc20) or SecMO (to reduce securin)(4). BubR1-depleted oocytes were injected with Cdc20 cRNA, SecMO or GFP cRNA and maintained for 2 h in IBMX before being washed into IBMX-free medium to allow resumption of meiosis along with uninjected controls and BubR1-depleted oocytes. Oocytes were scored for the presence of polar bodies by 10 h post-GVBD. Error bars, mean + SEM. Asterisks denote significant differences in mean PBE rates when compared with BubR1-depleted oocytes (P < 0.05; Student's t-test). Note that Cdc20 cRNA and SecMO significantly increased PBE rates whereas injection of GFP cRNA which acted as a control, had no effect. . Kinetochore-microtubule attachment defects in BubR1-depleted oocytes are not rescued by restraining securin expression or co-expressing Cdc20. We were interested in exploring whether kinetochore-microtubule defects observed after BubR1-depletion (Fig. 4) might be an indirect consequence of the accompanying Cdc20/securin mismatch. BubR1-depleted oocytes were co-injected with either Cdc20 cRNA (to increase Cdc20) or SecMO (to reduce securin)(4) as described in fig. S8 and immunostained at 8 h post-GVBD for tubulin, DNA and Mad2 along with BubR1-depleted oocytes and control oocytes (n ≥ 20 oocytes per group). As seen previously (see Fig. 4 ), BubR1-depleted oocytes (A) retain strong kinetochore Mad2 staining indicative of unattached kinetochores. In contrast, kinetochores in controls have become attached (Mad2 negative) by 8 h post-GVBD enabling chromosomes to become aligned (D). In BubR1-depleted oocytes, restraining securin expression (B) or co-expressing Cdc20 (C) does not rescue kinetochore attachment defects as these oocytes continue to demonstrate prominent kinetochore Mad2 along with misaligned chromosomes. Figure S10 . BubR1 is unstable when Cdh1 is depleted. We were interested in possible mechanisms by which BubR1 could influence the stability of Cdh1. We previously found that Cdh1 is unstable when BubR1 is depleted (see Fig. 3 , A and B) and that Cdh1 cannot be efficiently over-expressed on a BubR1-knockdown background (see fig. S6 ). Moreover, Cdh1 is stabilized when BubR1 is over-expressed ( fig. S4, A and B) . Together these data show that Cdh1 stability is dependent upon BubR1. We wanted to explore whether the converse was true, that is, if BubR1 stability might be influenced by Cdh1. (A) We first examined BubR1 levels in oocytes depleted of Cdh1. Samples (30 oocytes per time-point) of Cdh1-depleted oocytes were blotted for BubR1 and GAPDH alongside uninjected control oocytes at 3 h and 6 h post-GVBD. It can be seen that BubR1 levels are markedly reduced when Cdh1 is depleted. Note that Cdh1 was only partially depleted. (B) Next we investigated whether the efficiency of BubR1 over-expression would be affected by depletion of Cdh1. Uninjected controls and Cdh1-depleted oocytes were injected with hBubR1 cRNA and maintained for 2 h in 200 µM IBMX to allow time for hBubR1 translation. Samples (20 oocytes per time-point) were immunoblotted for BubR1 and GAPDH alongside uninjected oocytes at 3 h post-GVBD. Note that although hBubR1 can be over-expressed in Cdh1-depleted oocytes (lane 3), the levels attained are lower than when hBubR1 is over-expressed in Cdh1-replete oocytes (lane 2). Collectively, these data now show that BubR1 is unstable when Cdh1 is depleted. Overall therefore, our data show that BubR1 and Cdh1 are required for one another's stability. One possible model that would fit with these findings is that Cdh1 and BubR1 are competitive substrates. In mitosis, APCCdh1 is known to degrade both Cdh1(S18) and BubR1(S19). Intriguingly therefore, it is possible that Cdh1 and BubR1 are competitive substrates of APCCdh1 in oocytes. However, such a model would require refinement as the decreased BubR1 observed when Cdh1 levels (and hence APCCdh1 activity) are reduced (A) would be counter-intuitive to BubR1 being a substrate of APCCdh1. It is possible that different pools of Cdh1 exist, one of which forms a complex with BubR1, such complex formation conferring stability to both proteins. One could speculate that the BubR1-Cdh1 pool sets the amount of Cdh1 available to activate the APC. Decreased BubR1 might destabilise Cdh1 (and vice-versa) thereby reducing the Cdh1 available for APC activation. Alternatively, BubR1 and Cdh1 could be competitive substrates for the APC holoenzyme or for APC complexed with an as-yet-unidentified meiosis-specific co-activator. Figure S11 . Following Cdh1-depletion, Cdc20 levels are increased by 6 h and 8 h post-GVBD. A central theme of our model is that high securin levels after BubR1-depletion overwhelms late-acting APCCdc20, thereby preventing anaphase I and MI exit. Notably however, securin also over-accumulates after Cdh1-depletion (see Fig. 3 , D and E), yet these oocytes readily complete MI(6). This prompted us to investigate Cdh1-depleted oocytes more closely. Samples of Cdh1-depleted oocytes (20 oocytes per time-point) were collected along with uninjected oocytes at the GV-stage, 2 h, 4 h, 6 h and 8 h post-GVBD and immunoblotted for Cdc20, securin and actin. As before (see Fig. 3 , D and E), securin levels were higher after Cdh1-depletion. However, in contrast to BubR1-depleted oocytes in which Cdc20 levels do not increase by late MI (see Fig. 3 , A and C), we found that Cdc20 levels in Cdh1-depleted oocytes were roughly double those in controls by 6 h and 8 h post-GVBD thus arming these oocytes with sufficient APCCdc20 to cope with the increased securin load and enabling them to exit MI. In other words, by late MI, Cdh1-depleted oocytes have a favourable APCCdc20/securin ratio that enables them to complete MI transit. Differences in Cdc20 levels between BubR1-and Cdh1-depleted oocytes might be accounted for by less complete loss of Cdh1 in the former (see Fig. 1C ). That is, BubR1-depleted oocytes with more Cdh1 have greater APCCdh1-mediated Cdc20 destruction and hence less Cdc20. Less severe reduction of Cdh1 in BubR1-depleted oocytes would also accord with their lower rate of escape from prophase I arrest compared with Cdh1-depleted oocytes (see Fig 1B) .
